Aeon Biopharma, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
AMEX
Daewoong Co., Ltd. and Daewoong Pharmaceutical Co., Ltd. have increased their beneficial ownership in AEON Biopharma, Inc. to 49.99% through an exchange of convertible notes for common stock, a new note, and warrants.
AMEX
Daewoong Co., Ltd. and Daewoong Pharmaceutical Co. Ltd. report their beneficial ownership in AEON Biopharma, Inc. has fallen below 1% due to recent dilution and a reverse stock split.
AMEX
Robert J. Palmisano and The Palmisano Family, LLC have filed an amended Schedule 13D, revealing a beneficial ownership of 2,265,000 shares, representing approximately 5.7% of AEON Biopharma, Inc.'s Class A Common Stock.
AMEX
Robert J. Palmisano, a director of AEON Biopharma, Inc., and The Palmisano Family, LLC, have disclosed beneficial ownership of 2,265,000 shares, representing a 5.7% stake in the company's Class A Common Stock.